Trump’s eugenics obsession: He thinks he has “good German genes,” because he’s a fascist
By Heather Digby Parton,
Salon
| 09. 21. 2020
"Donald Trump speaking with supporters at a campaign rally at the Prescott Valley Event Center in Prescott Valley, Arizona" by Gage Skidmore licensed under CC by SA 2.0
Over the past five years or so, I've had no problem using the "F" word (fascism) to describe what's been happening under President Trump and the Republican Party. I wrote about it here in Salon all the way back in 2015, noting that I wasn't the only one. In fact, it was his fellow Republicans who were the first to use the term to describe him. All you have to do is go back and read that full-page newspaper ad Trump took out in 1989, headlined "Bring Back the Death Penalty, Bring Back Our Police," to understand his fundamental authoritarian nature.
Even though we knew from the beginning that we were dealing with an essentially authoritarian leader, our awareness of it has sometimes been subsumed amid the sheer chaos of daily news over the past five years. But if you look at the various issues Trump is most obsessed with, whether it was the lurid obsession...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...